1. Role of Industry in Clinical Care, Research and Education Rev 10/21/2014 APGO Interaction with Industry: A Medical Student Guide

2. Overview This presentation discusses the role of industry in clinical care, biomedical research and health care provider education. It can be a useful resource for multidisciplinary teams within your institution.

3. Objectives Discuss industry’s contributions to clinical care, research and education. Discuss the role of industry in the development of new drugs and medical devices and in the advancement of clinical care. Compare sources of support for the advancement of clinical care. At the completion of this presentation, participants will be able to:

4. Contributions to Clinical Care Significant contributions to local, regional, national and global health programs Provision of low-cost or free medications or devices to millions of patients around the globe

5. Role of Industry in Healthcare Advancement Performs research to advance diagnosis and treatment of disease Provides financial support to other organizations for research Stimulates and executes continuous development and improvement in drugs and devices Provides funding for health care provider educational programs, especially CME

6. Investment by Industry to Bring New Drugs or Devices to the US Market (hyperlinks will be active in presentation mode) According to Forbes, August 2013, the cost to bring a new drug to market is estimated at $5 billion. http://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new- drugs-is-shaping-the-future-of-medicine/ http://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new- drugs-is-shaping-the-future-of-medicine/ Process to bring a new drug or device to market is long and complex Go to http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm289601.htm to learn what it takes to bring a new drug to market http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm289601.htm Go to http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ HowtoMarketYourDevice/default.htm to learn what it takes to bring a new medical device to market http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ HowtoMarketYourDevice/default.htm

7. Contributions to Research Biomedical research expenditures by industry exceed that of the Federal government. In 2010, JAMA reported that by 2007, industry contributed the most money to biomedical research Industry = 58% NIH = 27% State and local governments = 5% Non Federal sources = 5% Not-for-profit = 4% JAMA. 2010;303(2):137-143. doi:10.1001/jama.2009.1987

8. Date of download: 7/9/2014 Copyright © 2014 American Medical Association. All rights reserved. From: Funding of US Biomedical Research, 2003-2008 JAMA. 2010;303(2):137-143. doi:10.1001/jama.2009.1987

9. Contributions to Education (hyperlinks will be active in presentation mode) Approximately 40% of clinical departments receive funding for resident and fellowship training Grants Devices, supplies Training time with industry representatives is necessary when new products or procedures are being introduced to healthcare providers As of 2006, approximately 62% of medical school CME income comes from commercial support http://www.ohsu.edu/xd/about/services/integrity/coi/gifts/upload/Financi al-Support-of-Continuing-Medical-Education.pdf http://www.ohsu.edu/xd/about/services/integrity/coi/gifts/upload/Financi al-Support-of-Continuing-Medical-Education.pdf As of 2012, 35-40% of CME delivered to healthcare professionals was funded by unrestricted educational grants from the pharmaceutical industry where pharma companies are not permitted to have any influence whatsoever on the content http://www.pm360online.com/why-pharma-should-continue-to-support-certified- cme/ http://www.pm360online.com/why-pharma-should-continue-to-support-certified- cme/

10. Promotional Spend by Industry is on the Decline http://www.skainfo.com/health_care_market_reports/2012_promotional_spending.pdfhttp://www.skainfo.com/health_care_market_reports/2012_promotional_spending.pdf Accessed 5/8/14 In 2012 we saw a greater overall drop in promotional spending than we observed the previous year, with 90% of decline attributable to detailing, sampling, and DTC. Spending in nearly every channel saw decline year over year in 2012, the only exception being mailings, which continued an upward trend.

11. Where Pharma is Investing their Promotional Dollars http://www.skainfo.com/health_care_market_reports/2012_promotional_spending.pdfhttp://www.skainfo.com/health_care_market_reports/2012_promotional_spending.pdf Accessed 5/8/14